None listed
Conditions
Interventions
Drug : 1) Hytrin administration group: Orally 1 tablet 5 mg QD for 16 weeks
2) Hytrin / Hinechol combined administration group: Oral use of Hytrin 5mg QD for 16 weeks and Hinechol 25mg 2 tablets BID
Sponsors
Cheongju ST.Mary's Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Men over 40 years old 2) Those with a total score of 8 or more in the International Prostate Symptom Score (IPSS) 3) Those who voluntarily decide to participate in this study and consent in writing to the subject's consent
Exclusion criteria
Exclusion criteria: 1) Those with hypersensitivity to Hythrin-based drugs (alpha-blocker) and Heinecol-based drugs (cholinergic drugs) 2) Those with clinically significant circulatory diseases (myocardial infarction, heart failure, angina, deep veins, pacemaker use, orthostatic hypotension, uncontrolled hypotension) 3) Those on hemodialysis 4) Those who show persistent oliguria due to renal function abnormalities 5) Patients with moderate hepatic impairment (Child-Pugh grade B) 6) Those who participated in other interventional clinical trials within 6 months of screening 7) Those who have a history of or present malignant tumors, and who are inadequate to participate in the study as judged by the principal investigator or the investigator. 8) Asthma patients, patients with hyperthyroidism 9) Others who are inadequate to participate in the research as judged by theprincipal investigator or the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostate Symptom Score change | — |
Secondary
| Measure | Time frame |
|---|---|
| Post-void residual urine change;Maximum flow rate change | — |
Countries
Korea, Republic of
Contacts
Public ContactTongwook Kim
Cheongju ST.Mary's Hospital
Outcome results
None listed